According to the recent research report titled ‘Global Cell and Gene Therapy Manufacturing Services Market is segmented by Type (Cell, Gene), Indication (Oncology, Cardiology, Orthopedic, Other), Mode (In-house, Contract), End-user Industry (Pharm & Biotechnology, Academic and Research Institute), Regional Forecasts 2021-2027’, available with MarketStudyReport, global cell and gene therapy manufacturing services market value stood at USD 7367.01 million in 2020 and is projected to record 12.34% CAGR over 2021-2027, subsequently amassing USD 15630.64 million by the end of the assessment period.
 

Global cell and gene therapy manufacturing services market growth is primarily driven by rising spending in research & development activities by pharmaceutical firms, increasing number of chronic diseases, orthopedic, and other cardiovascular disorders.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/4219699/
 

Notably, cell and gene therapy is transforming the way cancer patients and others with genetic abnormalities are treated. These novel therapy options significantly improve patient outcomes and, in certain cases, are curative.
 

Manufacturing such drugs, on the other hand, brings with it a slew of new obstacles. For instance, the manufacturing cost of these potentially game-changing drugs remains a significant obstacle to clinical translation and commercialization.
 

New technologies are required to manufacture high-quality drugs in a dependable and cost-effective manner. While new therapeutic options will help patients, the risk involved are still considered to be high for both the drug developers and patients.
 

Furthermore, rise in operational costs is likely to hamper worldwide cell and gene therapy manufacturing services industry progression over the study period.
 

Geographically, North America majorly contributes to the market revenue owing to increases cancer cases and strategic moves undertaken by major companies in the region. Moreover, various key players in the United States are taking strategic initiatives such as technological improvements, mergers, and others to develop new gene and cell therapy solutions.
 

On the other hand, Asia Pacific industry value is projected to rise significantly over 2021-2027, attributable to increased research & development in cell and gene therapy. Further, China is predicted to develop at the rapid rate throughout the projection period, due to rapid industrialization and an increase in the number of government approvals.
 

Leading organizations influencing global cell and gene therapy manufacturing services market trends are Cell and Gene Therapy Catapult, Wuxi Advanced Therapies, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, Takara Bio Inc., Catalent Inc. (Catalent Pharma Solutions), Lonza Group AG, Charles River Laboratories International Inc., Merck KGaA, and Thermo Fisher Scientific Inc.